Diagnostic performance of ¹⁸F-DCFPyL positron emission tomography/computed tomography for biochemically recurrent prostate cancer and change-of-management analysis.

ABSTRACT:

Introduction

Conventional imaging (CI) performs poorly to identify sites of disease in biochemically recurrent prostate cancer. ⁶⁸Ga-PSMA-11 positron emission tomography/computed tomography (PET/CT) is most studied but has a very short half-life. This study reports the diagnostic performance of the novel prostate-specific membrane antigen (PSMA) radiotracer ¹⁸F-DCFPyL using real-life data and tumor board simulation to estimate the impact of ¹⁸F-DCFPyL PET on patient management.

Methods

Ninety-three ¹⁸F-DCFPyL PET/CT scans performed for patients previously treated for prostate cancer with a rising prostate-specific antigen (PSA) were retrospectively compared to contemporary CI and clinical imaging and PSA followups. A chart review w

SUBMITTER: Chausse G 

PROVIDER: S-EPMC8195586 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature